Currently, cell therapy programmes under development at ECBio are based on UCX® and comprise two different therapeutic areas: cardiovascular disorders, such as peripheral artery disease and myocardial infarction, and immune-related disorders, such as rheumatoid arthritis. All programmes are based on the use of allogeneic UCX® cells in their undifferentiated state.

Technological platform overview and corresponding therapeutic applications currently under development at ECBio (all based on UCX® technology).

The cell therapy areas under the UCX® platform are currently being developed towards application in humans. The first two stages are the in vitro and in vivo proofs-of-concept, looking to demonstrate both safety and efficacy. Relevant animal model studies are being concluded in most areas. Peripheral artery disease and rheumatoid arthritis are initiating clinical trials.

State of development of ECBio’s cell therapy programmes for UCX® as of the end of 2015 and 2017, labelled in blue and green, respectively.